Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry Avorn

Showing results (301-310 of 308) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 308 results.
Drug Safety|May 14, 2015
Methodological approaches to evaluate the impact of FDA drug safety communicationsAaron S Kesselheim, Eric G Campbell, Sebastian Schneeweiss, et al.
Annals of Internal Medicine|May 6, 2004
The quality of pharmacologic care for vulnerable older patientsTakahiro Higashi, Paul G Shekelle, David H Solomon, et al.
JMIR Public Health and Surveillance|January 7, 2018
Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods AnalysisMichael S Sinha, Clark C Freifeld, John S Brownstein, et al.
BMJ Mental Health|February 6, 2026
Risk of neutropenia-related hospitalisation among clozapine initiatorsAmeet Sarpatwari, Mufaddal Mahesri, Joyce Lii, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|September 28, 2019
Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National SurveyAaron S Kesselheim, Michael S Sinha, Paula Rausch, et al.
Journal of Alzheimer'S Disease : JAD|April 11, 2022
Making the Case for Accelerated Withdrawal of AducanumabPeter Whitehouse, Sam Gandy, Vikas Saini, et al.
Drug Safety|April 27, 2021
A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) ProgramsAmeet Sarpatwari, Mayookha Mitra-Majumdar, Katsiaryna Bykov, et al.
The Journal of Pediatrics|December 26, 2016
Antibiotic Use in Children - A Cross-National Analysis of 6 CountriesIlan Youngster, Jerry Avorn, Valeria Belleudi, et al.
Pageof 31

Showing results (301-310 of 308) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 308 results.
Drug Safety|May 14, 2015
Methodological approaches to evaluate the impact of FDA drug safety communicationsAaron S Kesselheim, Eric G Campbell, Sebastian Schneeweiss, et al.
Annals of Internal Medicine|May 6, 2004
The quality of pharmacologic care for vulnerable older patientsTakahiro Higashi, Paul G Shekelle, David H Solomon, et al.
JMIR Public Health and Surveillance|January 7, 2018
Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods AnalysisMichael S Sinha, Clark C Freifeld, John S Brownstein, et al.
BMJ Mental Health|February 6, 2026
Risk of neutropenia-related hospitalisation among clozapine initiatorsAmeet Sarpatwari, Mufaddal Mahesri, Joyce Lii, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|September 28, 2019
Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National SurveyAaron S Kesselheim, Michael S Sinha, Paula Rausch, et al.
Journal of Alzheimer'S Disease : JAD|April 11, 2022
Making the Case for Accelerated Withdrawal of AducanumabPeter Whitehouse, Sam Gandy, Vikas Saini, et al.
Drug Safety|April 27, 2021
A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) ProgramsAmeet Sarpatwari, Mayookha Mitra-Majumdar, Katsiaryna Bykov, et al.
The Journal of Pediatrics|December 26, 2016
Antibiotic Use in Children - A Cross-National Analysis of 6 CountriesIlan Youngster, Jerry Avorn, Valeria Belleudi, et al.
Pageof 31